Chugai Pharmaceutical Co (CHGCF) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Chugai Pharmaceutical Co CHGCF is currently developing the following drugs: Enicepatide, Nxt007, Lorlatinib, Aqua07, Emicizumab, Nxt007, Nxt007, Human Coagulation Factor Viii, Donq52, Simulated Inadvertent Gluten Exposure Capsule, Obinutuzumab, Alps12, Aube00, Afimkibart, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Divarasib, Ray121, Sotorasib, Adagrasib, Divarasib, Bevacizumab, Atezolizumab, Tiragolumab, Gemcitabine, Nab-Paclitaxel, Nivolumab, Atezolizumab, Oxaliplatin, Capecitabine, S-1, Ro7496353, Atezolizumab, Rose12, Sail66, Satralizumab, Donq52, Satralizumab 120 Mg, Cetuximab, Luna18, Crovalimab, Spyk04, Eculizumab, Crovalimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.